



# Paediatric Disease Working Party

## Chairman: Selim Corbacioglu

Secretary: Katharina Kleinschmidt,

Vice Chair: Josu de la Fuente

Clinical Trial Committee Chair: Marc Ansari,

Statistician: Jacques-Emmanuel Galimard, Maud Ngoya

Study coordinator: Arnaud Dalissier


### Paediatric patients transplanted between 2010 and 2019

Patient Characteristics		N	%
Total number of HSCT		35212	
Total number of patients		30388	
Ratio HSCT/Patients		1.17	
Median age in years at diagnosis (Min-Max)		5(0-17)	
Median age in years at HSCT (Min-Max)		8.19(0,4-17.99)	
Gender	Male	17829	
	Female	12415	
Diagnosis	<b>Malignant diseases</b>		
	Acute leukaemia	11804	
	Chronic leukaemia	272	
	Lymphoma	1902	
	Plasma cell disorders	14	
	Solid tumours	7537	
	Myelodysplastic/Myeloproliferative	1787	
	<b>Non Malignant diseases</b>		
	Bone marrow failure	3600	
	Auto-immune diseases	164	
	Hemoglobinopathies	3307	


Transplant Characteristics					
		Malignant	%	Non-malignant disease	%
Conditioning regimen (excluding solid tumours)	MAC	11871	90.8	5094	77.0
	Non-myeloablative	1204	9.2	1525	23
	Missing	3101		597	
Type of transplant	Allogeneic	16286	59.1	7568	99.0
	Autologous	11269	40.9	75	1.0
	Missing	10		3	
Type of cells (alloHSCT)	BM	8581	53.1	5269	70.3
	PB	6011	37.2	1884	25.1
	CB	1577	9.8	338	4.5
	Other	0		1	
	Missing	128		79	
Type of donors (alloHSCT)	Identical sibling	4358	27.9	3801	50.9
	Relative	3196	20.5	1316	17.6
	Unrelated	7315	51.6	2352	31.5
	Missing	679		102	
TBI (age above 2 years old)	No	18718	78.5	6376	92.1
	Yes	5115	21.5	546	7.9
	Missing	1166		294	

Outcome Data					
		Malignant diseases	%	Non malignant diseases	%
Status at last follow up. n	Dead	5834	25.9	706	10.2
	Alive	16214	72.1	6044	87.2
	Lost to follow up	431	1.9	178	2.6
	Missing	825		143	
Cause of death	Relapse or progression	3589	63.7	51	7.7
	Secondary malignancy	39	0.7	7	1.1
	HSCT related	1704	30.2	515	78.0
	Other	305	5.4	87	13.2
	Missing	197		46	




### Number and type of HSCT for non-malignant diseases from 2010-2019



### Number and type of HSCT for malignant diseases from 2010-2019



### OS from first graft in malignant\* and non-malignant diseases



Please send of your proposal of study to us!

1)The proposal form can be either requested from the WP secretary or can be retrieved from the EBMT website of the PDWP.

2)Completed proposal forms should then be emailed to the PDWP chair, vice-chair, the secretary, and the Clinical Trials Committee chair Marc Ansari(Marc.Ansari@hcuge.ch)